» Articles » PMID: 30123774

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2018 Aug 21
PMID 30123774
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

There has been significant progress in utilizing our immune system against cancer, mainly by checkpoint blockade and T cell-mediated therapies. The field of cancer immunotherapy is growing rapidly but durable clinical benefits occur only in a small subset of responding patients. It is currently recognized that cancer creates a suppressive metabolic microenvironment, which contributes to ineffective immune function. Metabolism is a common cellular feature, and although there has been significant progress in understanding the detrimental role of metabolic changes of the tumor microenvironment (TEM) in immune cells, there is still much to be learned regarding unique targetable pathways. Elucidation of cancer and immune cell metabolic profiles is critical for identifying mechanisms that regulate metabolic reprogramming within the TEM. Metabolic targets that mediate immunosuppression and are fundamental in sustaining tumor growth can be exploited therapeutically for the development of approaches to increase the efficacy of immunotherapies. Here, we will highlight the importance of metabolism on the function of tumor-associated immune cells and will address the role of key metabolic determinants that might be targets of therapeutic intervention for improvement of tumor immunotherapies.

Citing Articles

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.


MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma.

Niveau C, Cettour-Cave M, Mouret S, Sosa Cuevas E, Pezet M, Roubinet B Nat Commun. 2025; 16(1):1083.

PMID: 39870647 PMC: 11772620. DOI: 10.1038/s41467-025-56392-x.


Identification and validation of a metabolic-related gene risk model predicting the prognosis of lung, colon, and breast cancers.

Khan J, Bareja C, Dwivedi K, Mathur A, Kumar N, Saluja D Sci Rep. 2025; 15(1):1374.

PMID: 39779736 PMC: 11711664. DOI: 10.1038/s41598-025-85366-8.


Physiologically Achievable Concentration of 2-Deoxy-D-Glucose Stimulates IFN-γ Secretion in Activated T Cells In Vitro.

Repas J, Frlic T, Snedec T, Kopitar A, Sourij H, Janez A Int J Mol Sci. 2024; 25(19).

PMID: 39408714 PMC: 11476708. DOI: 10.3390/ijms251910384.


Targeting lipid reprogramming in the tumor microenvironment by traditional Chinese medicines as a potential cancer treatment.

Zuo Q, Wu Y, Hu Y, Shao C, Liang Y, Chen L Heliyon. 2024; 10(9):e30807.

PMID: 38765144 PMC: 11101863. DOI: 10.1016/j.heliyon.2024.e30807.


References
1.
Wang R, Dillon C, Shi L, Milasta S, Carter R, Finkelstein D . The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35(6):871-82. PMC: 3248798. DOI: 10.1016/j.immuni.2011.09.021. View

2.
Patsoukis N, Weaver J, Strauss L, Herbel C, Seth P, Boussiotis V . Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Front Immunol. 2017; 8:330. PMC: 5387055. DOI: 10.3389/fimmu.2017.00330. View

3.
Lamb R, Harrison H, Hulit J, Smith D, Lisanti M, Sotgia F . Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5(22):11029-37. PMC: 4294326. DOI: 10.18632/oncotarget.2789. View

4.
Chen W, Wang J, Jia L, Liu J, Tian Y . Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 2016; 7:e2115. PMC: 4849159. DOI: 10.1038/cddis.2016.33. View

5.
Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K . De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014; 20(11):1327-33. DOI: 10.1038/nm.3704. View